Plain-language definitions grounded in the clinical and regulatory literature.
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Neuropeptide
What it isA pair of neuropeptides made in the lateral hypothalamus that keep you awake and alert. Without them, you fall asleep at the wrong times.
Why it mattersLoss of orexin-producing neurons causes narcolepsy. Drugs that block orexin (suvorexant, lemborexant, daridorexant) are FDA-approved treatments for insomnia.
Think of it like thisThink of orexin as the brain’s wakefulness throttle. When it’s running, you’re alert and awake. When the throttle fails, sleep barges in unannounced, that’s narcolepsy.
Two excitatory neuropeptides (orexin-A/HCRT1 and orexin-B/HCRT2) produced exclusively by neurons in the lateral hypothalamus, acting on G-protein-coupled receptors OX1R and OX2R to promote wakefulness, arousal, and motivated behavior.
MechanismOrexin neurons project broadly to wake-promoting nuclei (locus coeruleus, tuberomammillary nucleus, raphe) and stabilize wakefulness through OX2R signaling. Loss of these neurons (~70,000 cells in human) causes narcolepsy type 1, characterized by sleep-wake instability and cataplexy.
Scientific ConsensusOrexin is a primary wake-promoting neuropeptide. Loss of orexin neurons causes narcolepsy type 1. The OX2 receptor is the dominant sleep-wake regulator, while OX1 is more involved in motivation and reward.
Active DebateWhether dual orexin receptor antagonists and selective OX2 antagonists differ meaningfully in clinical outcomes. The role of orexin in mood disorders, addiction, and stress responses remains an active area of investigation.
Emerging ResearchOrexin receptor agonists (TAK-994, danavorexton) for narcolepsy treatment are in late-stage trials. The role of orexin in metabolic regulation, including links to obesity and feeding behavior. Potential applications in opioid use disorder treatment.
Key ResearchSakurai et al. (1998) and de Lecea et al. (1998) independently identified the peptides. Lin et al. (1999) and Chemelli et al. (1999) linked orexin loss to narcolepsy. Saper, Chou, and Scammell (2001) proposed the sleep-switch model. Suvorexant became the first orexin-targeting insomnia drug approved by FDA in 2014.
— Receptor pharmacology and OX1R/OX2R differential roles in sleep-wake regulation
— Comprehensive review of orexin within the broader sleep-wake circuitry
— Landmark Nature review establishing the hypothalamic sleep-switch model
— Foundational paper proposing orexin neurons as the stabilizing finger on the sleep-wake flip-flop
— Modern review of FDA-approved orexin receptor antagonists
Sleep disorders, PTSD, and the invisible wounds of service can feel isolating. If you or someone you know is in crisis or experiencing thoughts of self-harm, help is available right now. The Veterans Crisis Line provides free, confidential support 24 hours a day, 7 days a week to veterans, service members, and their families.
If you are in crisis or experiencing thoughts of self-harm, call the Veterans Crisis Line at